Longeveron (LGVN) Cash from Investing Activities (2020 - 2026)
Longeveron (LGVN) recorded quarterly Cash from Investing Activities of -$20000.0 in Q1 2026, up 68.75% quarter-over-quarter from -$64000.0 in Q4 2025, and up 86.67% on a YoY basis from -$10714.3 in Q1 2025.
Longeveron (LGVN) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Longeveron's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$20000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 86.67% year-over-year to -$20000.0; the TTM figure through Mar 2026 stood at -$465000.0 (up 42.16% YoY), while the FY2025 annual figure was -$595000.0, up 7.03% from the prior year.
- Cash from Investing Activities was -$20000.0 for Q1 2026 at Longeveron, up from -$64000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $3.8 million in Q3 2023 to a low of -$2.4 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged $367882.4 across 5 years, with a median of -$53000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities jumped 374.39% in 2023, then sank 1171.43% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$570000.0 in 2022, then surged by 374.39% to $1.6 million in 2023, then slumped by 107.86% to -$123000.0 in 2024, then soared by 47.97% to -$64000.0 in 2025, then surged by 68.75% to -$20000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$20000.0 (Q1 2026), -$64000.0 (Q4 2025), and -$118000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,000.00 |
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -64,000.00 |
| Dec 31, 2025 | -64,000.00 |
| Sep 30, 2025 | -118,000.00 |
| Sep 30, 2025 | -118,000.00 |
| Jun 30, 2025 | -263,000.00 |
| Jun 30, 2025 | -263,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Dec 31, 2024 | -123,000.00 |
| Dec 31, 2024 | -123,000.00 |
| Sep 30, 2024 | -478,000.00 |
| Sep 30, 2024 | -478,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Dec 31, 2023 | 1.56 Mn |
| Dec 31, 2023 | 1.56 Mn |